XML 64 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumables products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services. For a description of the products and services provided within each of the Company’s four reportable segments see Note 6, Segment and Geographic Information.

Net sales disaggregated by product category were as follows:
Year Ended December 31,
(in millions)202320222021
Equipment & Instruments$628 $678 $728 
CAD/CAM541 541 620 
Connected Technology Solutions$1,169 $1,219 $1,348 
Essential Dental Solutions$1,468 $1,427 $1,516 
Orthodontics$339 $297 $273 
Implants & Prosthetics 701 709 791 
Orthodontic and Implant Solutions$1,040 $1,006 $1,064 
Wellspect Healthcare$288 $270 $303 
Total net sales$3,965 $3,922 $4,231 


Net sales disaggregated by geographic region were as follows:
Year Ended December 31,
(in millions)202320222021
United States$1,437 $1,392 $1,480 
Europe1,550 1,559 1,675 
Rest of World978 971 1,076 
Total net sales$3,965 $3,922 $4,231 

Contract Assets and Liabilities

The Company generally does not have contract assets in the course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer aligner treatment where the performance obligation has not yet been fulfilled. The Company had deferred revenue of $91 million and $57 million recorded in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2023. The Company had deferred revenue of $91 million and $27 million recorded in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2022. The Company recognized $68 million of revenue during the twelve months ended December 31, 2023 which was previously deferred as of December 31, 2022. The Company recognized $59 million of revenue during the the twelve months ended December 31, 2022 which was previously deferred as of December 31, 2021. The Company expects to recognize a significant majority of the deferred revenue within the next twelve months.
Allowance for Doubtful Accounts

Accounts and notes receivable-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $17 million and $14 million at December 31, 2023 and 2022, respectively. For the years ended December 31, 2023 and 2022, changes to the provision for doubtful accounts including write-offs of accounts receivable that were previously reserved were insignificant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations.